https://edaravonechemical.com/....the-effect-with-the-
Of 499 clients, a total of 88 patients obtained neoadjuvant chemotherapy alone (n = 34) or in combination with bevacizumab (n = 54) within 3 months ahead of CRS/HIPEC. No variations existed in 60-day major morbidity (17.6 vs. 16.7%, p = 0.81) or 60-day death (0 vs. 0%) amongst the two cohorts, and neoadjuvant bevacizumab had not been associated with increased odds of total complications (OR 0.86, 95% CI 0.35-2.09, p = 0.73) or major morbidity (OR 0.86, 95% CI 0.24-3.00, p = 0.81). Stratifying custome
Like
Comment
Share
